$33.8m for renamed NeuroVista:
This article was originally published in Clinica
Executive Summary
NeuroVista this week confirmed its name change from BioNeuronics and reported completion of a series B financing. The proceeds of the funding totalled $33.8m, which the Seattle, Washington-based epilepsy treatment technology specialist aims to channel into the continuing development of its epilepsy-based devices and clinical research programme. The principal investment was made by Advanced Technology Ventures and Delphi Ventures, while series A investors Three Arch Partners, Sprout Group and Foundation Medical Partners also contributed in the round. Epilepsy's severity is outlined by the Epilepsy Foundation which reports 2.5 million people suffer from epilepsy in the US alone, costing the government an annual $15.5 bn.